SecBot SecBot
PRESS-RELEASE ·Filed Mar 18, 2026

LFWD

Lifeward Ltd.
MIXED
Impact 6/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The Oramed transaction could be transformative if executed, providing capital and a high-potential technology platform. However, deteriorating core financials and low cash reserves present near-term risk. Traders should monitor closing of the Oramed deal, execution on new product commercialization, and cash burn in 2026.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.72
T+0 close · Mar 18, 2026 · via day close
Latest settled
+1.19%
T+60 · $6.80
Vs SPY
−10.34%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 18 $6.72entry
  2. T+1 · 8mo ago +1.49%α +1.75% · $6.82
  3. T+5 · 8mo ago −2.83%α −2.11% · $6.53
  4. T+20 · 7mo ago −0.60%α −6.64% · $6.68
  5. T+60 · 5mo ago +1.19%α −10.34% · $6.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lifeward reported declining revenue and earnings for Q4 and full-year 2025, with Q4 revenue down 33% YoY to $5.1M and adjusted net loss widening. However, the company secured shareholder approval for a transformative strategic transaction with Oramed, gaining access to oral protein delivery technology and up to $47M in funding, which positions it for a potential turnaround. The deal, combined with cost reductions and strategic acquisitions, aims to drive future growth and achieve cash flow positivity.

Key Financial Metrics

Revenue
$22.0M
-14.1% YoY
Adj. EPS
$-13.23
GAAP: $-17.16
Deal Value
$47.0M

Key Facts

  • Q4 2025 revenue was $5.1M, down 33% YoY from $7.5M in Q4 2024
  • Full-year 2025 revenue declined 14% to $22.0M from $25.7M in 2024
  • Adjusted gross margin declined to 32.6% in Q4 2025 from 45.5% in Q4 2024
  • Adjusted net loss in Q4 2025 increased 27% to $4.2M from $3.3M in Q4 2024
  • Shareholder approval obtained for strategic transaction with Oramed, providing up to $47M in funding
  • Lifeward to acquire Oramed’s POD™ oral protein delivery technology; Oramed to take up to 49.99% equity stake
  • Company acquired powered upper-body exoskeleton tech to expand ReWalk platform
  • Reimbursement expanded with Aetna, Humana, and UnitedHealthcare covering ReWalk under Medicare Advantage
  • Cash balance was $2.2M as of December 31, 2025, down from $6.7M in 2024

Financial Impact

Revenue declined by $3.7M (-14%) in 2025; adjusted operating loss increased to $15.1M from $16.6M in 2024; transaction with Oramed could bring up to $47M in non-dilutive funding

revenuegross_marginoperating_lossnet_lossliquidity

Risk Factors

  • Low cash balance ($2.2M) raises near-term liquidity concerns
  • Core revenue and profitability trends are deteriorating despite cost-cutting
  • Oramed transaction is not yet closed and subject to final conditions
  • High customer concentration and reliance on reimbursement expansions

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258091

Track record

25 reports on LFWD

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +20.27% at T+60 after the Aug 14, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Bearish 6/10 Entry $4.06 Now $3.62 +10.84% settles Nov 20
  2. Nov 12, 20264d ago 3 Neutral 1/10 Entry $4.06 Now $3.62 −10.84% settles Nov 20
  3. Nov 3, 202613d ago 3 Neutral 2/10 Entry $6.06 to $5.76 Now $3.62 −40.26% ▼ −4.95% −4.04% vs SPY
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $6.04 to $5.83 Now $3.62 −40.07% ▼ −3.48% −1.49% vs SPY
  5. Oct 8, 20265w ago 8-K Bearish 5/10 Entry $6.49 to $6.00 Now $3.62 +44.22% ▲ +7.55% +5.58% vs SPY
  6. Oct 1, 20266w ago 8-K Neutral 2/10 Entry $5.96 to $6.43 Now $3.62 −39.26% ▲ +7.89% +6.58% vs SPY
  7. Sep 25, 20267w ago DEF 14A Bearish 7/10 Entry $6.92 to $6.67 Now $3.62 +47.69% ▲ +3.61% +4.82% vs SPY
  8. Aug 14, 202613w ago 8-K Mixed 6/10 No price data
  9. Aug 14, 202613w ago Press Release Bearish 6/10 Entry $7.45 to $7.32 Now $3.62 +51.41% ▲ +1.75% +0.38% vs SPY
  10. Aug 11, 202614w ago EFFECT Bearish 7/10 Entry $7.57 to $7.41 Now $3.62 +52.15% ▲ +2.08% +1.67% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 18, 2026